<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>21208833</identifier>
<setSpec>1579-2021</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Hernández Mijares, Antonio</dc:author>
<dc:author>Carey, Vincent J</dc:author>
<dc:author>Hermans, Michel P</dc:author>
<dc:author>Salas, Xavier Pintó</dc:author>
<dc:author>Sacks, Frank M</dc:author>
<dc:author>Fruchart, Jean-Charles</dc:author>
<dc:author>Montoya, Juan Pedro-Botet</dc:author>
<dc:author>Millán Núñez-Cortés, Jesús</dc:author>
<dc:description xml:lang="en">The R3i Foundation (Residual Risk Reduction Initiative), an independent, multinational and academic organization, is conducting the REALIST (Residual Risk, Lipids and Standard Therapies) study in 40 centers in different countries. This is a retrospective epidemiological study, designed to provide new data on the residual risk of major coronary events attributable to lipid abnormalities in patients receiving the current standard treatment. The initial results are expected in mid 2010, and the overall results at the end of 2010.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2011 Jan </dc:date>
<dc:title xml:lang="es">Estudio REALIST (REsiduAl risk, LIpids and Standard Therapies): un análisis del riesgo residual dependiente del perfil lipídico en el síndrome coronario agudo.</dc:title>
<dc:title xml:lang="en">[The REALIST (REsiduAl risk, LIpids and Standard Therapies) study: an analysis of residual risk attributable to lipid profile in acute coronary syndrome].</dc:title>
<dc:publisher>Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion</dc:publisher>
</metadata>
</record>
</pubmed-document>
